First-line albumin-bound paclitaxel (ABRAXANE) is a National Comprehensive Cancer Network® (NCCN®) Category 1 recommended option for advanced NSCLC1

NCCN recommendations for ABRAXANE in non-small cell lung cancer
aOf negative or unknown EGFR mutation and ALK status.
ECOG=Eastern Cooperative Oncology Group; PS=performance status; EGFR=epidermal growth factor receptor; ALK=anaplastic lymphoma kinase.

NCCN recommends albumin-bound paclitaxel (ABRAXANE) + carboplatin as a first-line therapy option for patients with advanced NSCLC and good ECOG PS (0-1) who have negative or unknown EGFR mutation and ALK status.1

Category 1: Based on high-level evidence, there is uniform NCCN® consensus that the intervention is appropriate.1

First-line albumin-bound paclitaxel (ABRAXANE) is a National Comprehensive Cancer Network® (NCCN®) Category 1 recommended option for advanced NSCLC1

NCCN recommendations for ABRAXANE in non-small cell lung cancer
aOf negative or unknown EGFR mutation and ALK status.
ECOG=Eastern Cooperative Oncology Group; PS=performance status; EGFR=epidermal growth factor receptor ALK=anaplastic lymphoma kinase.

NCCN recommends albumin-bound paclitaxel (ABRAXANE) + carboplatin as a first-line therapy option for patients with advanced NSCLC and good ECOG PS (0-1) who have negative or unknown EGFR mutation and ALK status.1

Category 1: Based on high-level evidence, there is uniform NCCN®consensus that the intervention is appropriate.1

View response data from the clinical trial

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.